E1 association practice Flashcards
(106 cards)
1
Q
P16 or P53
A
tumor suppressor
2
Q
CDK4/6 cell cycle phase
A
g1
3
Q
CYP19
A
aromatase
steroidal/non-steriodal
androgens to estrogens
4
Q
lymphoid lineage
A
glucocorticoids
5
Q
antag and agonist effects
A
tamoxifen
6
Q
adipocytes
A
source of estrogen in post meno women
7
Q
6.5
A
prostate cancer
8
Q
flare
A
GnRH analogs (leuprolide, goselerin)
feminization
9
Q
17-a-hydrolase and CYP17
A
Abiraterone
10
Q
-lutamide
A
Androgen receptor antagonists
11
Q
inactive confirmation
A
type II kinase inhibitor
12
Q
t790M
A
resistance to gefitinib
use osimertinib to treat
13
Q
covalent
A
Afatinib
Osimertinib
Acalabrutinib
14
Q
mesenchymal
A
sarcoma
15
Q
both EGFR and HER2
A
lapatinib
16
Q
sxs of CHF
A
lapatinib, trast/pert
17
Q
GOAL
A
EGFR inhibitors
18
Q
FLT3
A
myeloid leukemia
midostaurin
crenolanib
quizartinib
19
Q
ITD mutations
A
quizartinib
20
Q
Philadelphia
A
Bcr-Abl
CML
Imatinib
Ponatinib
21
Q
T315, gatekeeper
A
Ponatinib
22
Q
EML4-ALK
A
wild type
alectinib
23
Q
BRAF-V600
A
dabrafenib
24
Q
Dabrafenib
A
BRAF-V600
wild type
combo with trametinib
25
trametinib
MEK1 and MEK2
rash
allosteric (type III)
combo with dabraf
26
BTK
B cells
Ibrutinib
Acalabrutinib
27
Cys481
Acalabrutinib
28
mTOR
rapamycin analogs
-limus drugs
serine-threonine kinase
29
interfere with pyrimidine nucleotide synthesis
5-FU
capecitabine
30
Inhibit DNA polymerase alpha
Cytarabine and Gemcitabine
31
thymidylate synthase
5-FU
32
DPD
5-FU
33
Thymidine
5-FU rescue
34
5-FU synergy
leucovorate
35
Capecitabine
prodrug of 5-FU
36
Cytidine deaminase
Cytarabine
37
DNA polymerase alpha
Ara-CTP Cytarabine shit
38
tetrahydrouridine
cytidine deaminase inhibitor
cytarabine combo for effiacy
39
block purine synthesis
6-MP
40
TPMT
6-MP genetic shit
41
allopurinol
6-MP
xanthine oxidase
42
6-TG
allopurinol does NOT block breakdown
43
DHFR
folic acid/folates
TMP synthesis
methotrexate
44
methotrexate rescue
leucovorin
reverse toxic effects of DHFR inhibition
45
intrastrand and interstrand
dna alkylation
46
second malignancies
alkylators
47
all alkylators SE
myelosuppression
48
aryl group
chlorambucil
decrease nucleophilicity
49
hydroxylation by CP450
cyclophosphamide
50
aldehyde dehydrogenase
cyclophosphamide
acrolein
51
acrolein
cyclophosphamide
aldehyde dehydrogenase
52
hemorrhagic cystitis
acrolein
cyclophosphamide
53
mesna
cyclophosphamide
bladder
urine
54
bifunctional adducts
mitomycin C (alkylator)
55
prodrug (4)
tamoxifen
capecitabine
irinotecan (SN38)
cyclophosphamide
56
crosslinkers
platinum drugs
cisplatin
alkylators
57
cisplatin
intrastrand
aquo form shit
58
nephrotoxicity
ototoxicity
cisplatin
59
increased expression resistance class glutathione-S-transferase (GST)
alkylating agents
60
flu-like sxs with CHF risk
trastuzumab
61
inhibit dimerization drug
pertuzumab
62
CLEOPATRA
trast and pertuz
HER2+
63
EGF and TGF-alpha
Cetuximab
64
CYP2d6
tamoxifen
65
severe infusion reaction
xi drugs
66
VEGF
angiogenesis
bevacizumab
67
CD20
b cells (non-hodgkins)
rituximab
Ofatumumab
68
CD38
daratumumab
69
HER2/Neu
trastuzumab emtansine
70
CD3 and CD19
blinatumomab
Target T cells
also think CD3 apparently
71
CD3 and CD20
Mosunetuzumab
72
CTLA-4 and PD1 purpose
reactivate T cells
73
bind to CTLA-4
Ipilimumab
73
PD-1 location
on T cells
74
bind PD-1
pembrolizumab
75
Binds PDL-1
Atezolizumab
76
expressed on macrophages on tumor cells
PDL-1
77
PAP-GM-CSF
sipulcel-T
stimulate immune system to attack cancer
78
isolates T cells
CAR-T
79
CD19
target for CAR-T
80
topo I cleavage
S phase
81
Glutathione-s-transferase overexpression
resistance in topo I inhibitors
82
UGT1A1
Irinotecan polymorphism increases toxicity
83
SN-38
Irinotecan active metabolite
84
Topo I phase
S
85
anthracycline
topo II
doxorubicin
86
cardiotoxicity
doxorubicin
free radicals
dextra drug
87
G2/M block cell cycle
etoposide
vincristine
bleomycin
88
kinectochore
spindle assembly
microtubule inhibitors
89
peripheral neuropathy
vinca alkaloids
90
neurotoxicity and severe local inflammation
vincristine
vinca
91
taxane bind
tubulin
block depolymerization
92
Poor PGP substrate
epothilones (ixabepilone)
93
Proteasome activity
Bortezomib
94
ubiquitin
bortezomib
proteasome
95
potent teratogen
thalidomide
96
cereblon
pomalidomide
PROTACs
97
BCL-2
venetoclax
98
intercalators
irinotecan
bleomycin
doxorubicin
99
23% lung cancers
EGFR mutations
100
drug enhances t cell activation
ipilimumab
101
no requirement of chemical or enzymatic change drug
doxorubicin
102
5-azacytidine
DNA methyltransferase
103
BCR
CD20 works in combo with
104
L85R mutation
afatinib
105
allosteric
trametinib
